Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: Results from a randomized, placebo-controlled trial

Psychiatry Research

Volumn 161, Issue 3, 2008, Pages 284-291

  Emsley, Robin ^a   Niehaus, Dana J H ^a   Oosthuizen, Petrus P ^a   Koen, Liezl ^a   Ascott Evans, Brynne ^b   Chiliza, Bonginkosi ^a   van Rensburg, Susan J ^c   Smit, Retha M ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Bleeding time; Eicosapentaenoic acid; Fatty acid; Glucose; Lipids; Omega 3; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOPENTHIXOL; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC AGENT; ICOSAPENTAENOIC ACID; MOOD STABILIZER; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PROLACTIN;

ADULT; AKATHISIA; APPETITE DISORDER; ARTICLE; BLEEDING TIME; BODY MASS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE METABOLISM; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; POST ICTAL DELIRIUM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 55749111529     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2007.06.029     Document Type: Article

References (37)

1. Ahmed A.A., and Holub B.J. Alteration and recovery of bleeding times, platelet aggregation and fatty acid composition of individual phospholipids in platelets of human subjects receiving a supplement of cod-liver oil. Lipids 19 (1984) 617-624
2. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry 62 Suppl 7 (2001) 22-31
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth edition (1994), American Psychiatric Association, Washington, D.C
4. Balk E.M., Lichtenstein A.H., Chung M., Kupelnick B., Chew P., and Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189 1 (2006) 19-30
5. Belluzi A., Brignola C., Campieri M., Pera A., Boschi S., and Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. New England Journal of Medicine 334 (1996) 1557-1560
6. Broughton K.S., Johnson C.S., Pace B.K., Liebman M., and Kleppinger K.M. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. Journal of Clinical Nutrition 65 (1997) 1011-1017
7. Caniato R.N., Alvarenga M.E., and Garcia-Alcaraz M.A. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Australian and New Zealand Journal of Psychiatry 40 (2006) 691-697
8. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. Journal of Clinical Psychiatry 63 Suppl 9 (2002) 5-11
9. Department of Health and Human Services. United States of America. Food and Drug Administration. 21 CFR Part 184 (Docket No. 86G-0289). Federal Register. Vol. 62, No 108/ Thursday, June 5, 1997. Rules and Regulations (1997) 30751-30757
10. Emsley R., Oosthuizen P., and van Rensburg S.J. Clinical potential of omega-3-fatty acids in the treatment of schizophrenia. CNS Drugs 17 15 (2003) 1081-1091
11. Emsley R., Niehaus D., Koen L., Oosthuizen P., Turner H.J., Carey P., Janse van Resnburg S., Maritz F.S., and Murck H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomised, placebo-controlled trial. Schizophrenia Research 84 1 (2006) 112-120
12. Farmer A., Montori V., Dinneen S., and Clar C. Fish oil in people with type II diabetes mellitus. Cochrane Database of Systematic Reviews 4 (2001)
13. Fenton W.S., Hibbeln J., and Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 47 (2000) 8-21
14. Freeman M.P. Omega-3 fatty acids in psychiatry: a review. Annals of Clinical Psychiatry 12 (2000) 159-165
15. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., Keck P.E., Marangell L.B., Richardson A.J., Lake J., and Stoll A.L. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry 67 12 (2006) 1954-1967
16. Gaw A. HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. Cardiovascular Drugs and Therapy 17 (2003) 53-62
17. Goldman L.S. Medical illness in patients with schizophrenia. Journal of Clinical Psychiatry 60 Suppl 21 (1999) 10-15
18. Goodnight Jr. S.H., Harris W.S., and Connor W.E. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood 58 (1981) 880-885
19. Harrison-Woolrych M., and Clark D. Nose bleeds associated with use of risperidone. British Medical Journal 328 (2004) 1416
20. Hooper L., Thompson R.L., Harrison R.A., Summerbell C.D., Moore H., Worthington H.V., Durrington P.N., Ness A.R., Capps N., Davey Smith G., Riemersma R.A., and Ebrahim S.B. Omega-3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews 4 (2004)
21. Horrobin D.F., and Bennett C.N. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins, Leukotrienes and Cancer 60 (1999) 141-167
22. International Conference on Harmonization. ICH Harmonised Tripartite Guidelines for Good Clinical Practice (1996), Brookwood Medical Publications Ltd, Surrey
23. Joy C.B., Mumby-Croft R., and Joy L.A. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews (2003) CD001257
24. Kremer J.M., Lawrence D.A., Petrillo G.F., Litts L.L., Mullaly P.M., Rynes R.I., Stocker R.P., Parhami N., Greenstein N.S., and Fuchs B.R. Effects of high dose fish oil on rheumatoid arthritis after stopping non-steroidal antiinflammatory drugs. Arthritis and Rheumatism 38 (1995) 1107-1114
25. Morris M.C., Sacks F., and Rosner B. Does fish-oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88 (1993) 523-533
26. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28 Suppl 1 (2003) 83-96
27. Parker G., Gibson N.A., Brotchie H., Heruc G., Rees A.M., and Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. American Journal of Psychiatry 163 6 (2006) 969-978
28. Pejic R.N., and Lee D.T. Hypertriglyceridemia. Journal of the American Board of Family Medicine 19 (2006) 310-316
29. Ryan M.C., and Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sciences 71 (2002) 239-257
30. Samaha F.F. Effect of very high fat diets on body weight, lipoproteins, and glycaemic status in the obese. Current Atherosclerosis Reports 7 (2005) 412-420
31. Stensby N.E. Nutritional properties of fish-oils. World Review of Nutrition and Dietetics 11 (1969) 46-105
32. Thorngren M., and Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet 2 (1981) 1190-1193
33. Topliss J.G., Clark A.M., Ernst E., Hufford C.D., Johnston G.A.R., Rimoldi J.M., and Weimann B.J. Natural and synthetic substances related to human health (IUPAC Technical Report). Pure and Applied Chemistry 74 (2002) 1957-1985
34. Tracy R.P. Diet and hemostatic factors. Current Atherosclerosis Reports 1 (1999) 243-248
35. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vascular Health Risk Management 2 3 (2006) 251-262
36. von Schacky C. Omega-3 fatty acids and cardiovascular disease. Current Opinion in Clinical Nutrition and Metabolic Care 10 2 (2007) 129-135
37. Wojenski C.M., Silver M.J., and Walker J. Eicosapentaenoic acid ethyl ester as an antithrombotic agent: comparison to an extract of fish oil. Biochimica et Biophysica Acta 1081 (1991) 33-38